The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2025. This month there are two technology appraisals and one health technology evaluation that impact upon primary care.
The Dapagliflozin for treating chronic kidney disease technology appraisal has been published. This treatment is recommended as an option to treat chronic kidney disease (CKD) in adults, if:
- it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor antagonists, unless these are contraindicated, and
- people have an estimated glomerular filtration rate (eGFR) of:
- 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or
- 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2, and either:
- a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or
- type 2 diabetes
The Cenobamate for treating focal onset seizures in epilepsy technology appraisal has been updated. As reported in May, amendments to some recommendations were made to reduce inequity of access to the treatment. This update has amended the 'why the committee made these recommendations' section to reflect the updated recommendations.
The One-piece closed bags for colostomies: late-stage assessment health technology evaluation has been published. This is a late stage assessment, an approach to evaluate technologies that are already in widespread use within the NHS. It is noted that there is not enough evidence to determine whether price variation is justified between different one-piece closed bags for adults with a colostomy. It is recommended that stoma care services should have access to a broad range of one-piece closed bags available for prescription in the NHS, so that adults with a colostomy can have the most appropriate bag for them. A joint decision between a healthcare professional and the person with a colostomy should take into account clinical appropriateness and the person with a colostomy's needs and preferences. Where more than one product is suitable, the least expensive option should be used.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.